India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>Anupam has moved from a largely India-based custom-synthesis company to an integrated platform spanning fluorine inputs, specialty molecules, U.S. manufacturing and finished pharmaceutical formulations.</li>
<li>The integration strategy has coincided with record FY26 revenue, a sharp recovery in operating cash flow and materially better inventory and receivable days.</li>
<li>The thesis is no longer just growth through capex. It is now about extracting returns from acquired assets while ensuring minority-funded consolidation translates into attributable earnings and cash.</li>
</ul>


Anupam has moved from a largely India-based custom-synthesis company to an integrated platform spanning fluorine inputs, specialty molecules, U.S. manufacturing and finished pharmaceutical formulations.
The integration strategy has coincided with record FY26 revenue, a sharp recovery in operating cash flow and materially better inventory and receivable days.
The thesis is no longer just growth through capex. It is now about extracting returns from acquired assets while ensuring minority-funded consolidation translates into attributable earnings and cash.


Anupam Rasayan: The Vertical Integration Playbook

Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Thematic (Sector/Industry)

<ul>
<li>Aether Industries, Anupam Rasayan and Acutaas Chemicals are developing international chemical opportunities; Linde India is positioning around gas supply for India’s emerging manufacturing ecosystem.</li>
<li>Chemical suppliers can address established overseas demand before India’s new commercial fabs begin volume production. </li>
<li>Acutaas’ Korean operation and Anupam’s US acquisition also show that exporting molecules can evolve into manufacturing close to customers.</li>
</ul>


Aether Industries, Anupam Rasayan and Acutaas Chemicals are developing international chemical opportunities; Linde India is positioning around gas supply for India’s emerging manufacturing ecosystem.
Chemical suppliers can address established overseas demand before India’s new commercial fabs begin volume production. 
Acutaas’ Korean operation and Anupam’s US acquisition also show that exporting molecules can evolve into manufacturing close to customers.


Semiconductor Chemicals: Four Listed Indian Companies, Two Different Markets

<ul>
<li>Anupam Rasayan signed an SPA on May 23, 2026, to acquire up to 48.2% in Bliss GVS Pharma at INR 299/share, triggering a 26% open offer.</li>
<li>This is Anupam’s third major acquisition in18 months, expanding from raw materials to CDMO and branded pharma, while adding INR 927 crore revenue and a debt-free Balance Sheet.</li>
<li>The deal cost is around INR 1,370 crore. Returns will depend on how quickly Anupam uses Bliss GVS’s EU-GMP licenses and 60-country distribution network to sell its own molecules downstream.</li>
</ul>


Anupam Rasayan signed an SPA on May 23, 2026, to acquire up to 48.2% in Bliss GVS Pharma at INR 299/share, triggering a 26% open offer.
This is Anupam’s third major acquisition in18 months, expanding from raw materials to CDMO and branded pharma, while adding INR 927 crore revenue and a debt-free Balance Sheet.
The deal cost is around INR 1,370 crore. Returns will depend on how quickly Anupam uses Bliss GVS’s EU-GMP licenses and 60-country distribution network to sell its own molecules downstream.


Anupam Rasayan’s Pharma Pivot: From Molecules to Medicines

<ul>
<li>Fluorine chemistry is gaining strategic importance across sectors like pharma, agrochemicals, EVs, and semiconductors, driven by the superior thermal, chemical, and biological properties of fluorinated compounds. </li>
<li>India is emerging as a global hub in fluorination, supported by backward-integrated capacities, decades of handling expertise, and the global China+1 diversification strategy. </li>
<li>Companies like <a href="https://www.smartkarma.com/entities/srf-ltd" target="_blank" data-smartkarma-citation="entities:3601:1" rel="noopener">SRF Ltd (SRF IN)</a>, <a href="https://www.smartkarma.com/entities/gujarat-fluorochemicals-limited" target="_blank" data-smartkarma-citation="entities:44112:1" rel="noopener">Gujarat Fluorochemicals (FLUOROCH IN)</a>, and <a href="https://www.smartkarma.com/entities/navin-fluorine-international" target="_blank" data-smartkarma-citation="entities:3511:1" rel="noopener">Navin Fluorine International (NFIL IN)</a> are scaling up across the value chain from fluoropolymers to battery-grade electrolytes.</li>
</ul>


Fluorine chemistry is gaining strategic importance across sectors like pharma, agrochemicals, EVs, and semiconductors, driven by the superior thermal, chemical, and biological properties of fluorinated compounds. 
India is emerging as a global hub in fluorination, supported by backward-integrated capacities, decades of handling expertise, and the global China+1 diversification strategy. 
Companies like SRF Ltd (SRF IN), Gujarat Fluorochemicals (FLUOROCH IN), and Navin Fluorine International (NFIL IN) are scaling up across the value chain from fluoropolymers to battery-grade electrolytes.


Thematic Report: All You Need to Know About Fluorination Industry in India

Consumer Analyst / Channel Surveillance Specialist, Trudence Capital Advisors

Pranav Bhavsar

Consumer Analyst / Channel Surveillance Specialist

Trudence Capital Advisors

Trudence Capital Advisors Private Limited is a SEBI-registered Research Analyst, holding SEBI registration number INH000015747. Our firm is dedicated to providing independent and unbiased research on Indian mid to large-cap companies. Trudence Capital is known for its counter-consensus views, with a focus on forensic research and on-ground primary investigations. Our research approach is thorough, involving detailed analysis of accounting practices and governance, alongside extensive channel checks.

Independent & Unbiased Research

<ul>
<li>This insight explores the semiconductor industry's fundamental building blocks, focusing on India's role and target segments within the value chain.</li>
<li>The Indian government has committed INR 76,000 crore to establish a self-reliant semiconductor manufacturing ecosystem.</li>
<li>Key investments are being made in semiconductor manufacturing, focusing on design, assembly, testing, and packaging capabilities.</li>
</ul>


This insight explores the semiconductor industry's fundamental building blocks, focusing on India's role and target segments within the value chain.
The Indian government has committed INR 76,000 crore to establish a self-reliant semiconductor manufacturing ecosystem.
Key investments are being made in semiconductor manufacturing, focusing on design, assembly, testing, and packaging capabilities.


Thematic Building Block | India's Semiconductor Push

India

Anupam Rasayan is a leading Indian company specializing in the custom synthesis and manufacturing of specialty chemicals. They provide high-value intermediates for diverse end-markets including agrochemicals, pharmaceuticals, personal care, and performance materials. The company was founded in 1984 and is headquartered in Surat, Gujarat, India.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Anupam Rasayan (ANURAS IN)

Anupam Rasayan: The Vertical Integration Playbook

How Anupam Rasayan is using upstream security, overseas manufacturing and downstream pharma integration to build a larger platform, while trying to...

Sudarshan Bhandari

Semiconductor Chemicals: Four Listed Indian Companies, Two Different Markets

Indian companies are preparing for semiconductor value chain. Two methods- Chemicals and Gases, Chemicals offers export opportunity vs Gases offer...

Nimish Maheshwari

Anupam Rasayan’s Pharma Pivot: From Molecules to Medicines

Anupam Rasayan acquires 48.2% in Bliss GVS Pharma, third major acquisition in 18 months, adding revenue and expanding capabilities.

Sudarshan Bhandari

Thematic Report: All You Need to Know About Fluorination Industry in India

Fluorine chemistry's strategic importance is growing in various sectors, with India emerging as a global hub in fluorination, supported by...

Nimish Maheshwari

Thematic Building Block | India's Semiconductor Push

India is investing heavily in its semiconductor industry to establish a self-reliant manufacturing ecosystem, with a focus on key segments within...

Pranav Bhavsar

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Anupam Rasayan: The Vertical Integration Playbook

How Anupam Rasayan is using upstream security, overseas manufacturing and downstream pharma integration to build a larger platform, while trying to...

Sudarshan Bhandari

Semiconductor Chemicals: Four Listed Indian Companies, Two Different Markets

Indian companies are preparing for semiconductor value chain. Two methods- Chemicals and Gases, Chemicals offers export opportunity vs Gases offer...

Nimish Maheshwari

Anupam Rasayan’s Pharma Pivot: From Molecules to Medicines

​Anupam Rasayan acquires 48.2% in Bliss GVS Pharma, third major acquisition in 18 months, adding revenue and expanding capabilities.

Sudarshan Bhandari

Thematic Report: All You Need to Know About Fluorination Industry in India

​Fluorine chemistry's strategic importance is growing in various sectors, with India emerging as a global hub in fluorination, supported by...

Nimish Maheshwari

Thematic Building Block | India's Semiconductor Push

​India is investing heavily in its semiconductor industry to establish a self-reliant manufacturing ecosystem, with a focus on key segments within...

Pranav Bhavsar

Anupam Rasayan acquires 48.2% in Bliss GVS Pharma, third major acquisition in 18 months, adding revenue and expanding capabilities.

Fluorine chemistry's strategic importance is growing in various sectors, with India emerging as a global hub in fluorination, supported by...

India is investing heavily in its semiconductor industry to establish a self-reliant manufacturing ecosystem, with a focus on key segments within...